You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Quest's CEO gave an overview of the firm's business and the lab space in general, while GenMark launched a new system this week aimed at smaller labs.
Among the diagnostic firms presenting at the conference on Tuesday were lab giant LabCorp, diversified medical products firm Hologic, and MDx startups, such as Adaptive Biotechnologies.
Several of the top molecular diagnostic firms presented at the JP Morgan Healthcare Conference on Monday discussing product portfolios, FDA clearances, and plans for 2018.
The company attributed the revenue increase to strong sales of its ePlex molecular diagnostics systems.
For its first fiscal quarter, the firm's diagnostics business revenues are expected to drop to $285 million from $325 million in the prior-year quarter.
The firm said that it expects to report a 12 percent year-over-year increase in molecular diagnostics product revenues, driven by Verigene and Aries placements.
The company also expects to report a 31 percent increase in full-year 2017 revenues.
The infectious disease diagnostics firm added it secured seven new contracts during the fourth quarter.
The company said that it expects its fourth quarter revenues will be up as much as 380 percent over the year-ago quarter.
The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35.